ACC 2022: FIDELITY Demonstrates Benefits of Finerenone in the Primary and Secondary Prevention Settings
The drug consistently reduced cardiovascular and kidney outcomes regardless of cardiovascular history
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.